Nautilus Biotechnology Inc
NASDAQ:NAUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nautilus Biotechnology Inc
Net Income (Common)
Nautilus Biotechnology Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
Net Income (Common)
-$59m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Income (Common)
$6.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
13%
|
|
|
Danaher Corp
NYSE:DHR
|
Net Income (Common)
$3.7B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
|
Waters Corp
NYSE:WAT
|
Net Income (Common)
$642.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Net Income (Common)
$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Income (Common)
$1.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
37%
|
CAGR 10-Years
13%
|
|
Nautilus Biotechnology Inc
Glance View
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
See Also
What is Nautilus Biotechnology Inc's Net Income (Common)?
Net Income (Common)
-59m
USD
Based on the financial report for Dec 31, 2025, Nautilus Biotechnology Inc's Net Income (Common) amounts to -59m USD.
What is Nautilus Biotechnology Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-30%
Over the last year, the Net Income (Common) growth was 17%. The average annual Net Income (Common) growth rates for Nautilus Biotechnology Inc have been -1% over the past three years , -30% over the past five years .
